SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?


To: rkrw who wrote (951)6/25/2002 7:36:44 PM
From: keokalani'nui  Respond to of 1834
 
PFE or MRK, Worldwide, less Japan.

40% royalty on sales; they pay to register in Europe.

Co-promote right in US, if sales <$250m after 3 years or any year thereafter.

Retain mftg but subcontract to licensor under separate mftg k.

NDA approval = payment of 75% all development/clinical costs.

Signing bonus: $25m and pick up the tab for dinner.

Plus whatever language would have improved WLA's chances for independence from PFE.